Analyst Price Target Update on Illumina (NASDAQ:ILMN)

Illumina (NASDAQ:ILMN) should head towards $157.46 per share according to 13 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $125 per share. The higher price estimate target is at $235 according to the Analysts.

Many analysts have stated their opinion on the company shares. In a research note released to the investors, Citigroup maintains its rating on Illumina (NASDAQ:ILMN).The analysts at the brokerage house have a current rating of Buy on the shares. In a recent information released to the investors, Citigroup lowers the new price target from $210 per share to $175 per share. The rating by the firm was issued on May 4, 2016. Company shares have received an average consensus rating of Hold for the current week

On the companys insider trading activities, Eastham Karin, director of Illumina Inc, unloaded 5,000 shares at an average price of $145.01 on June 1, 2016. The total amount of the transaction was worth $725,050, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.

Illumina (NASDAQ:ILMN) stock ended Monday session in the red zone in a volatile trading. The stock closed down 1.91 points or 1.35% at $139.71 with 913,807 shares getting traded. Post opening the session at $140.44, the shares hit an intraday low of $139.415 and an intraday high of $143.775 and the price was in this range throughout the day. The company has a market cap of $20,565 million and the number of outstanding shares have been calculated to be 147,200,000 shares. The 52-week high of Illumina (NASDAQ:ILMN) is $242.37 and the 52-week low is $127.1.

Illumina, Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems, consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms, reagent kits and scanning equipment. Its customers include genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories, pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research, including de novo sequencing, genetic variation analysis, epigenetics and targeted screening, among others. It also provides products and services for other life sciences applied markets, such as agrigenomics. It also offers Clarity Run Manager, Clarity LIMS Silver and Clarity LIMS Gold.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.